Clinical Trials Logo
  1. Home
  2. Methamphetamine Use Disorder
  3. NCT01982643

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder — ADAPT  

Methamphetamine Use Disorder Clinical Trial

Official title:
CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT) for Methamphetamine Use Disorder

Clinical Trial Summary

The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a combination of extended-release depot naltrexone plus extended-release bupropion as a potential pharmacotherapy for methamphetamine (MA) use disorder.

Clinical Trial Description

Stage 1 will include 20 individuals with severe stimulant use disorder (methamphetamine type) enrolled across three study sites. Following a maximum 30-day screening period to establish eligibility, participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks. Take-home oral study medication (BRP) will be dispensed weekly for dosing on non-clinic days. Participants will be asked to attend clinic twice weekly for observed BRP dosing, collection of urine samples, assessments, and medical management. Following the 8-week active medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visit during Week 9. If Stage 1 data document success (see criteria below) in at least 3 "responder" study participants, Stage 2 will follow utilizing the same protocol as in Stage 1, to enroll an additional group of 29 participants. Using the same criteria of "responder" success, if the combined stages document success in at least 9 of 49 study participants, the combination medication will be considered to have shown sufficient potential to advance to a large-scale placebo-controlled trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01982643
Study type Interventional
Source University of California, Los Angeles
Contact
Status Completed
Phase Phase 1/Phase 2
Start date November 2013
Completion date February 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT04178993 - Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] Phase 1
Completed NCT03078075 - Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Phase 3
Not yet recruiting NCT06320366 - Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder N/A
Terminated NCT05711862 - The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder Phase 2
Recruiting NCT05322954 - Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder Phase 1
Recruiting NCT05760807 - Intranasal Oxytocin for Methamphetamine Withdrawal in Women N/A
Recruiting NCT04614584 - Mirtazapine and Methamphetamine Drug-drug Interaction Study Phase 1
Recruiting NCT05558358 - Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder Phase 1/Phase 2
Active, not recruiting NCT06279273 - A Study for the Risky Decision-making Deficits Among Methamphetamine Dependence Individuals and Treatment N/A
Active, not recruiting NCT04907357 - rTMS for Stimulant Use Disorders N/A
Completed NCT04713124 - A Telephone-delievered Intervention to Reduce Methamphetamine Use N/A
Active, not recruiting NCT04791969 - Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM Phase 2
Completed NCT00572234 - Bupropion in the Treatment of Methamphetamine Dependence N/A
Terminated NCT03106571 - Study of Pomaglumetad and Methamphetamine Phase 1
Recruiting NCT06033365 - Beginning Early and Assertive Treatment for Methamphetamine Use Disorder N/A